Genomic profiling of inflammatory breast cancer: A review

Breast

Volumn 23, Issue 5, 2014, Pages 538-545

  Bertucci, François ^a,b   Finetti, Pascal ^a   Vermeulen, Peter ^c,d   Van Dam, Peter ^d   Dirix, Luc ^c,d   Birnbaum, Daniel ^a   Viens, Patrice ^a,b   Van Laere, Steven ^c,d,e  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

DNA microarrays; Genome profiling; Inflammatory breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DNA; MICRORNA; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATORY BREAST CANCER; INNATE IMMUNITY; MOLECULAR BIOLOGY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATORY BREAST NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908176760     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.06.008     Document Type: Review

References (52)

1. Dawood S., Merajver S.D., Viens P., Vermeulen P.B., Swain S.M., Buchholz T.A., et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011, 22:515-523.
2. Pierga J.Y., Petit T., Delozier T., Ferrero J.M., Campone M., Gligorov J., et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012, 13:375-384.
3. Chevallier B., Asselain B., Kunlin A., Veyret C., Bastit P., Graic Y. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer 1987, 60:897-902.
4. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. JAm Coll Surg 1995, 180:297-306.
5. Ueno N.T., Buzdar A.U., Singletary S.E., Ames F.C., McNeese M.D., Holmes F.A., et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997, 40:321-329.
6. Charafe-Jauffret E., Tarpin C., Viens P., Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol 2008, 35:41-50.
7. Silvera D., Arju R., Darvishian F., Levine P.H., Zolfaghari L., Goldberg J., et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009, 11:903-908.
8. Boussen H., Cristofanilli M., Zaks T., DeSilvio M., Salazar V., Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. JClin Oncol 2010, 28:3248-3255.
9. Bertucci F., Finetti P., Birnbaum D., Viens P. Gene expression profiling of inflammatory breast cancer. Cancer 2010, 116:2783-2793.
10. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Nasser V., Loriod B., et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004, 64:8558-8565.
11. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Cervera N., Tarpin C., et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005, 65:2170-2178.
12. Van Laere S., Van der Auwera I., Van den Eynden G.G., Fox S.B., Bianchi F., Harris A.L., et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005, 93:237-246.
13. Van Laere S., Van der Auwera I., Van den Eynden G., Van Hummelen P., van Dam P., Van Marck E., et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer 2007, 97:1165-1174.
14. Bièche I., Lerebours F., Tozlu S., Espie M., Marty M., Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004, 10:6789-6795.
15. Nguyen D.M., Sam K., Tsimelzon A., Li X., Wong H., Mohsin S., et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006, 12:5047-5054.
16. Dressman H.K., Hans C., Bild A., Olson J.A., Rosen E., Marcom P.K., et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006, 12:819-826.
17. Boersma B.J., Reimers M., Yi M., Ludwig J.A., Luke B.T., Stephens R.M., et al. Astromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008, 122:1324-1332.
18. van Golen K.L., Davies S., Wu Z.F., Wang Y., Bucana C.D., Root H., et al. Anovel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999, 5:2511-2519.
19. Van Laere S.J., Van der Auwera I., Van den Eynden G.G., Elst H.J., Weyler J., Harris A.L., et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 2006, 12:3249-3256.
20. Thomas Z.I., Gibson W., Sexton J.Z., Aird K.M., Ingram S.M., Aldrich A., et al. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br J Cancer 2011, 104:1575-1586.
21. Van Laere S.J., Ueno N.T., Finetti P., Vermeulen P., Lucci A., Robertson F.M., et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res 2013, 19:4685-4696.
22. Lerebours F., Vacher S., Andrieu C., Espie M., Marty M., Lidereau R., et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008, 8:41.
23. Gotzmann J., Mikula M., Eger A., Schulte-Hermann R., Foisner R., Beug H., et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004, 566:9-20.
24. Giampieri S., Manning C., Hooper S., Jones L., Hill C.S., Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009, 11:1287-1296.
25. Giampieri S., Pinner S., Sahai E. Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res 2010, 70:3435-3439.
26. Colpaert C.G., Vermeulen P.B., Benoy I., Soubry A., van Roy F., van Beest P., et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003, 88:718-725.
27. Kleer C.G., van Golen K.L., Braun T., Merajver S.D. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001, 14:458-464.
28. Charafe-Jauffret E., Tarpin C., Bardou V.J., Bertucci F., Ginestier C., Braud A.C., et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. JPathol 2004, 202:265-273.
29. Ren Y., Wu L., Frost A.R., Grizzle W., Cao X., Wan M. Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer. Mol Cancer 2009, 8:111.
30. Bertucci F., Ueno N.T., Finetti P., Vermeulen P., Lucci A., Robertson F.M., et al. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and survival. Ann Oncol 2014, 25:358-365.
31. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. JClin Oncol 2005, 23:7265-7277.
32. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
33. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., et al. Astroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15:68-74.
34. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. JClin Oncol 2006, 24:4236-4244.
35. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
36. Denkert C., Loibl S., Noske A., Roller M., Müller B.M., Komor M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. JClin Oncol 2010, 28:105-113.
37. Masuda H., Baggerly K.A., Wang Y., Iwamoto T., Brewer T., Pusztai L., et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 2013, 15:R112.
38. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121:2750-2767.
39. Ahomadegbe J.C., Tourpin S., Kaghad M., Zelek L., Vayssade M., Mathieu M.C., et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene 2000, 19:5413-5418.
40. Lerebours F., Bertheau P., Bieche I., Driouch K., De The H., Hacene K., et al. Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer 2002, 102:618-622.
41. Lerebours F., Bertheau P., Bieche I., Plassa L.F., Champeme M.H., Hacene K., et al. Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res 2003, 9:4184-4189.
42. Bekhouche I., Finetti P., Adelaïde J., Ferrari A., Tarpin C., Charafe-Jauffret E., et al. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS One 2011, 6:e16950.
43. Fernandez S.V., Robertson F.M., Pei J., Aburto-Chumpitaz L., Mu Z., Chu K., et al. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat 2013, 140:23-33.
44. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
45. Alpaugh K.R., Bingham C., Fittipaldi P., Wu H., Banzi M., Palmer G., et al. Mutation discordance between tissue sources from the same patient. Third International Inflammatory Breast Cancer Conference, Philadelphia, PA, USA 2012, Oral presentation.
46. Van der Auwera I., Yu W., Suo L., Van Neste L., van Dam P., Van Marck E.A., et al. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 2010, 5:e12616.
47. Van der Auwera I., Limame R., van Dam P., Vermeulen P.B., Dirix L.Y., Van Laere S.J. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 2010, 103:532-541.
48. Lerebours F., Cizeron-Clairac G., Susini A., Vacher S., Mouret-Fourme E., Belichard C., et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer 2013, 133:1614-1623.
49. Zhang E.Y., Cristofanilli M., Robertson F., Reuben J.M., Mu Z., Beavis R.C., et al. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. JProteome Res 2013, 12:2805-2817.
50. Xiao Y., Ye Y., Zou X., Jones S., Yearsley K., Shetuni B., et al. The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction. Oncogene 2011, 30:287-300.
51. Lehman H.L., Dashner E.J., Lucey M., Vermeulen P., Dirix L., Van Laere S., et al. Modeling and characterization of inflammatory breast cancer emboli grown invitro. Int J Cancer 2013, 132:2283-2294.
52. Robertson F.M., Chu K., Fernandez S.V., Mu Z., Zhang X., Liu H., et al. Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of epithelial plasticity and suppression of TGFβ signaling. JClin Exp Pathol 2012, 2:119.